.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,851,451

« Back to Dashboard

Details for Patent: 5,851,451

Title: Production of microspheres
Abstract:Disclosed is a method of producing microspheres which comprises subjecting a w/o/w emulsion or o/w emulsion to an in-water drying method under the following conditions: 1) the amount of microspheres per m.sup.3 of an external aqueous phase is about 0.1 to about 500 kg, 2) the square root of the area (unit: m.sup.2) of the liquid surface in contact with the gas phase is about 0.2 to about 4.5 per the cube root of the volume (unit: m.sup.3) of an external aqueous phase, 3) the w/o/w emulsion or o/w emulsion is replaced at the replacement frequency of about 0.01 to about 10 times/minutes, 4) a gas is blown to the w/o/w emulsion or o/w emulsion at the gas transfer rate near the liquid surface of about 0.1 to about 300 m/second, and 5) the gas is replaced at the replacement frequency of not less than about 0.5 times/minutes; and the method of the present invention increases the rate of solvent removal from microspheres in in-water drying, reduces the amount of solvent in microspheres in a short time.
Inventor(s): Takechi; Nobuyuki (Osaka, JP), Ohtani; Seiji (Osaka, JP), Nagai; Akihiro (Osaka, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Filing Date:Dec 13, 1996
Application Number:08/766,611
Claims:1. A method of producing microspheres comprising a physiologically active substance and a biodegradable polymer, which comprises subjecting a w/o/w emulsion or o/w emulsion wherein said physiologically active substance is in an inner aqueous phase and said biodegradable polymer is in an external oil phase to an in-water drying method under the following conditions:

1) the amount of microspheres per m.sup.3 in an external aqueous phase is about 0.1 to about 500 kg,

2) the square root of the area (unit: m.sup.2) of the liquid surface in contact with the gas phase is about 0.2 to about 4.5 per the cube root of the volume (unit: m.sup.3) of the external aqueous phase,

3) the w/o/w emulsion or o/w emulsion is replaced at a replacement frequency of about 0.01 to about 10 times/minute,

4) a gas is blown toward the w/o/w emulsion or o/w emulsion so that the gas transfer rate near the liquid surface is about 10 to 300 m/second, and

5) the gas is replaced at a replacement frequency of not less than about 0.5 times/minute.

2. The method according to claim 1, wherein the amount of microspheres per m.sup.3 in the external aqueous phase is about 0.5 to about 100 kg.

3. The method accordingly to claim 1, wherein the square root of the area (unit: m.sup.2) of the liquid surface in contact with the gas phase is about 0.5 to about 3.0 per the cube root of the volume (unit: m.sup.3) of the external aqueous phase.

4. The method according to claim 1, wherein the physiologically active substance is a physiologically active peptide.

5. The method according to claim 1, wherein the physiologically active substance is an LH-RH agonist or an LH-RH antagonist.

6. The method according to claim 1, wherein the biodegradable polymer is a biodegradable polymer having a free terminal carboxyl group.

7. The method according to claim 1, wherein the biodegradable polymer is a lactic acid/glycolic acid polymer.

8. The method according to claim 1, wherein the gas transfer rate near the liquid surface is about 10 to about 200 m/second.

9. The method according to claim 1, wherein the gas transfer rate near the liquid surface is about 50 to about 150 m/second.

10. The method according to claim 7, wherein the composition ratio of a lactic acid/glycolic acid is from about 90/10 to about 50/50.

11. The method according to claim 1, wherein the physiologically active substance is a substance selected from the group consisting of LH-RH agonist, LH-RH antagonist, antitumor agent, antibiotic, antipyretic agent, analgesic, anti-inflammatory agent, antitussive expectorant, sedative, muscle relaxant, antiepileptic, antiulcer agent, antidepressant, anti-allergic agent, cardiotonic, antiarrhythmic agent, vasodilator, hypotensive diuretic, antidiabetic, antihyperlipidemic agent, anticoagulant, hemolytic, antituberculosis agent, hormone, narcotic antagonist, bone resorption suppressor, osteogenesis promoter and angiogenesis inhibitor.

12. The method according to claim 1, wherein the physiologically active substance is:

(1) a peptide represented by the formula:

wherein R.sub.1 represents His, Tyr, Trp or p-NH.sub.2 -Phe; R.sub.2 represents Tyr or Phe; R.sub.3 represents Gly or a D- amino acid residue; R.sub.4 represents Leu, Ile or Nle; R.sub.5 represents (a) Gly-NH--R.sub.6 wherein R.sub.6 is H or an alkyl group with or without a hydroxyl group or (b) NH--R.sub.7 wherein R.sub.7 is H, an alkyl group with or without an amino or a hydroxyl group, or (c) ureido (--NH--CO--NH.sub.2); or

(2) a peptide represented by the formula: ##STR13## wherein X represents hydrogen atom or tetrahydrofuryl-carboxamide; Q represents hydrogen atom or methyl; A represents nicotinoyl or N,N'-diethylamidino; B represents isopropyl or N,N'-diethylamidino; or a salt thereof.

13. The method according to claim 1, wherein the physiologically active substance is leuprorelin or leuprorelin acetate.

14. A method of producing microspheres comprising a physiologically active substance and a biodegradable polymer, which comprises subjecting a w/o/w emulsion or o/w emulsion wherein said physiologically active substance is in an inner aqueous phase and said biodegradable polymer in an external oil phase to an in-water-drying method under the following conditions:

1) the amount of microspheres per m.sup.3 in an external aqueous phase is about 0.1 to about 500 kg,

2) the square root of the area (unit: m.sup.2) of the liquid surface in contact with the gas phase is about 0.2 to about 4.5 per the cube root of the volume (unit: m.sup.3) of the external aqueous phase,

3) the w/o/w emulsion or o/w emulsion is replaced at a replacement frequency of about 0.01 to about 10 times/minute,

4) a gas is blown toward the w/o/w emulsion or o/w emulsion so that the gas transfer rate near the liquid surface is about 10 to about 200 m/second, and

5) the gas is replaced at a replacement frequency of not less than about 0.5 times/minute,

wherein the physiologically active substance is leuprorelin or leuprorelin acetate, and

the biodegradable polymer is a lactic acid/glycolic acid polymer having a composition ratio of about 90/10 to 50/50.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc